Prevalence of LPS in Gram-negative bacterial udder infections determines mastitis severity and disease prognosis. This pilot study explores the notion that milk-soluble (s) LPS/IgG complex levels in dairy cows link mastitis severity to intramammary Gram-negative infections during early lactation. Milk, within a single herd, was analysed from (i) 34 early lactating cows with acute mastitis and (ii) milk selected from peak lactation cows displaying either healthy (SCC < 100 × 103 cells/mL, n = 146) or subclinical mastitis (SCC > 150 × 103 cells/mL, n = 135) characteristics. Milk was assessed for (i) sLPS/IgG using an “in-house” ELISA, (ii) udder inflammation using LDH activity, and (iii) bacterial presence applying on-farm and standard microbiological laboratory techniques. Mean milk sLPS/IgG absorbances in acute mastitis cows were higher than those detected in healthy and subclinical mastitis cows, with mean differences of 0.35 (95% CI, 0.28 to 0.42) and 0.36 (95% CI, 0.28 to 0.44), respectively. On day 1 of acute mastitis, sLPS/IgG levels in milk containing only Gram-positive bacteria ranged from OD 0.04 to 0.14 (median = 0.1). In contrast, sLPS/IgG levels ranging from OD 0.27 to 1.42 (median = 0.58) and from 0.02 to 1.67 (median = 0.21) were detected in milk containing only Gram-negative bacteria or both Gram-negative and Gram-positive bacteria (i.e., polymicrobial), respectively. Furthermore, differential milk sLPS/IgG absorbance profiles (observed during the testing period days 1–3) were observed in cows with acute mastitis caused by Gram-positive, Gram-negative or polymicrobial infections. Our preliminary findings support the notion that milk sLPS/IgG complexes provide a link between mastitis severity and intramammary Gram-negative infections in dairy cows during early lactation.

NEW ZEALAND VETERINARY JOURNAL

Association between milk anti- Staphylococcus aureus antibody, somatic cell count, and milk yield in lactating dairy cows

Article

作者: McDougall, S ; Koralagamage Don, R ; Pernthaner, A

AIMS:

To assess the association between the sample/positive (S/P) ratios from a milk IgG ELISA, specific for Staphylococcus aureus and the somatic cell count (SCC) in cow composite milk samples taken at routine herd testing, and the association between the S/P ratio and milk solids (MS; kg fat + protein/cow/day) in cows in a pasture-based, seasonal-calving, New Zealand dairy herd.

METHODS:

Data from cow-composite milk samples were retrospectively analysed to determine the associations between the S/P ratios from a milk IgG ELISA specific for S. aureus, SCC (transformed to linear scores (LS) for analysis), and MS from cow-composite milk samples collected on four occasions across two lactations. A generalised linear mixed model was used to assess the effect of age, breed, month in lactation, and their interactions on the S/P ratio. To assess agreement between cows defined as infected based on S/P and on SCC, cows were classified as uninfected or infected using test positive cutpoints ≥ 0.38 for the S/P ratio and ≥ 150,000 cells/mL for SCC, and the agreement between these categories was compared by Gwet's agreement coefficient (AC). A generalised linear mixed model was used to assess associations between S/P and MS production with age, breed, and herd test date, with their interactions as explanatory variables, and cow as a random effect.

RESULTS:

The S/P varied by month of lactation, and there was an interaction between age and breed. There was a moderate agreement between the dichotomised S/P ratios and the dichotomised SCC (Gwet's AC = 0.59 (SE = 0.02); p < 0.001). When the MS production of cows defined as S/P test negative, suspicious or positive was analysed, there was an age by S/P interaction whereby there was no association between S/P category and MS amongst 2-year-olds, while in older cows, test-positive cows had lower MS than test-negative cows.

CONCLUSIONS:

This observational study demonstrated moderate agreement between S/P ratio and SCC. Additionally, there were negative associations between the S/P ratio and MS amongst older cows and in late lactation. Thus, the S/P ratio of an S. aureus-specific IgG ELISA is correlated with a well-defined marker of mastitis (SCC) and with milk yield depression. Further assessment of these associations using microbiology, and investigation of associations between the antibody results and long-term survival in the herd would further strengthen the validity and utility of the test.

项与 Koru Biotech Solutions Ltd. 相关的新闻（医药）

2021-12-23

·NS Medical Devices

KORU Medical Systems Receives FDA 510(k) Clearance for the Use of the FREEDOM60 with Two Additional SCIg Drugs

The Freedom Syringe Infusion System currently includes the FREEDOM60 and FreedomEdge Syringe Infusion Drivers, Precision Flow Rate Tubing and HIgH-Flo Subcutaneous Safety Needle Sets Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced FDA 510(k) clearance that expands on-label use of the FREEDOM60 Infusion System to two additional subcutaneous Ig (SCIg) medications, Cutaquig®, manufactured by Octapharma, and Xembify®, manufactured by Grifols. “We are excited to announce another milestone for KORU Medical as we seek to further improve patients’ quality of life through the development and delivery of high-quality therapeutic drug delivery in the home. Having the FREEDOM60 Infusion System cleared for use with Xembify and Cutaquig allows patients and providers additional options for life enhancing subcutaneous immunoglobulin therapy treatment in the home with a system that has broad patient and healthcare worker adoption,” said Linda Tharby, President and CEO. “KORU Medical’s Freedom Infusion System is specifically cleared for use with more SCIg drugs than any other system. Adding Xembify and Cutaquig to our label, in addition to our recent FDA 510(k) clearance for use of Hizentra® prefilled syringes with the FreedomEdge®, extends KORU Medical’s leadership position in the growing SCIg market.” KORU Medical Systems develops, manufactures, and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings.

100 项与 Koru Biotech Solutions Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Koru Biotech Solutions Ltd. 相关的转化医学

登录后查看更多信息